News und Analysen
UnitedHealth Group's Sales Surge Above $50 Billion, Despite Exiting Obamacare
UnitedHealth Group's (NYSE: UNH) decision to stop selling Obamacare plans this year hasn't dented its momentum. The nation's biggest health insurer reported sales of $50 billion in the second quarter
How Risky Is Organovo Holdings, Inc.?
You probably won't be shocked to learn that Organovo Holdings, Inc. (NASDAQ: ONVO) has historically been a risky stock. After all, the share price of the 3D bioprinting company dropped nearly 36% in
Here's Why Quidel Corporation Is Rising Today
Shares of Quidel Corporation (NASDAQ: QDEL), a company focused on diagnostic testing equipment, rose 11% as of 11:45 a.m. EDT on Tuesday in response to the announcement that it is acquiring a few
Here's Why Novavax, Inc. Stock Popped Today
Shares of Novavax, Inc. (NASDAQ: NVAX), a clinical-stage biotech focused on novel vaccine development, jumped 24.6% higher as of 11:50 a.m. EDT on Tuesday. Investors are cheering in response to the
UnitedHealth Sees a Healthier Future
Healthcare is front and center in Washington once more, and lawmakers have made little progress toward making anticipated changes on the insurance front. In the absence of more reform efforts, health
UnitedHealth Sees a Healthier Future
Healthcare is front and center in Washington once more, and lawmakers have made little progress toward making anticipated changes on the insurance front. In the absence of more reform efforts, health
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Johnson & Johnson (NYSE: JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to other parts of the healthcare
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Johnson & Johnson (NYSE: JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to other parts of the healthcare
AveXis Inc.: Buy at the High?
In the time it takes most newborns to sprout their first teeth, AveXis Inc. (NASDAQ: AVXS) looks ready to sink its teeth into the biotech industry. Since its market debut in early 2016, stellar
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
3 Healthcare Stocks for Ambitious Investors
While we Fools generally prefer to invest in companies that have battle-tested business models, we do recognize that it can be a smart idea to swing for the fences every now and then.So which stocks
3 Healthcare Stocks for Ambitious Investors
While we Fools generally prefer to invest in companies that have battle-tested business models, we do recognize that it can be a smart idea to swing for the fences every now and then.So which stocks
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
It's that time again, folks: Earnings season is kicking into full swing. And with that comes healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) quarterly report, which often sets the tone for the
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
It's that time again, folks: Earnings season is kicking into full swing. And with that comes healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) quarterly report, which often sets the tone for the
Should Mazor Robotics' Investors Fear the Incoming Competition?
Many industry experts believe that the robotic surgery market is on the cusp of a dramatic expansion. For example, a recent report from marketsandmarkets.com predicts that the market will grow from
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share